Insider Selling: Guardian Pharmacy Services, Inc. (NYSE:GRDN) Director Sells 201,303 Shares of Stock

Guardian Pharmacy Services, Inc. (NYSE:GRDN - Get Free Report) Director John Ackerman sold 201,303 shares of Guardian Pharmacy Services stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $20.16, for a total value of $4,058,268.48. Following the completion of the transaction, the director now directly owns 149,794 shares of the company's stock, valued at $3,019,847.04. This represents a 57.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

John Ackerman also recently made the following trade(s):

• On Tuesday, May 27th, John Ackerman sold 1,084,276 shares of Guardian Pharmacy Services stock. The stock was sold at an average price of $20.16, for a total value of $21,859,004.16.

Guardian Pharmacy Services Trading Up 0.6%

Shares of GRDN traded up $0.12 during midday trading on Monday, hitting $21.29. The company's stock had a trading volume of 249,308 shares, compared to its average volume of 168,739. Guardian Pharmacy Services, Inc. has a one year low of $14.16 and a one year high of $26.91. The company's fifty day simple moving average is $23.18 and its two-hundred day simple moving average is $22.01.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.01). The company had revenue of $329.31 million during the quarter, compared to analyst estimates of $321.21 million. Equities analysts anticipate that Guardian Pharmacy Services, Inc. will post 0.87 EPS for the current fiscal year.

Institutional Investors Weigh In On Guardian Pharmacy Services

A number of hedge funds have recently made changes to their positions in the stock. R Squared Ltd acquired a new position in Guardian Pharmacy Services during the 4th quarter worth approximately $30,000. BNP Paribas Financial Markets acquired a new stake in Guardian Pharmacy Services in the fourth quarter valued at approximately $37,000. Compass Financial Services Inc bought a new stake in shares of Guardian Pharmacy Services during the fourth quarter worth $58,000. JPMorgan Chase & Co. acquired a new position in shares of Guardian Pharmacy Services during the fourth quarter worth $77,000. Finally, Quantbot Technologies LP acquired a new position in shares of Guardian Pharmacy Services during the fourth quarter worth $81,000.

Analysts Set New Price Targets

GRDN has been the subject of several recent analyst reports. Raymond James set a $28.00 price objective on shares of Guardian Pharmacy Services and gave the stock an "outperform" rating in a research report on Wednesday, May 14th. Truist Financial restated a "buy" rating and issued a $28.00 target price (up from $25.00) on shares of Guardian Pharmacy Services in a research report on Monday, May 19th. Finally, Wall Street Zen downgraded shares of Guardian Pharmacy Services from a "buy" rating to a "hold" rating in a report on Saturday, May 24th.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.